Patient Switching Behaviors Impact on Adherence and Engagement: A Predictive Analytics and Machine Learning Approach to Improving Hub Performance and Patient Outcomes Today we have access to more data, from more sources than we could ever…
ARE EXISTING REGULATORY EVIDENCE STANDARDS ADEQUATE FOR INFORMING DECISIONS ON MEDICAL DEVICE ADOPTION BY U.S. HEALTHCARE PROVIDERS/HOSPITALS? Virtual ISPOR 2020 | MONDAY, May 18th, 2020 | 11:00 AM ET MODERATOR: Nicole Ferko, MSC, EVERSANA ISSUE: With cost containment…
Widespread hope exists that aducanumab will soon gain Food and Drug Administration approval as the first disease-modifying therapy for patients with mild cognitive impairment associated with Alzheimer disease (AD), which could significantly impact the management of…
In a PM360 Focus on Payer Strategies feature, Brian Davis addresses the question: Besides efforts to lower drug prices and increase transparency, what market access challenges/barriers will cause pharma companies the most stress this year? How…
The Growing Potential of Connected IoT In PharmaVOICE’s Showcase on Connected Health and IoT, Ed Cox offers executive viewpoints on the challenges of integrating the Internet of Medical Things (IoMT) into pharma processes. “Breaking down siloes…
The New Roaring 20s: How Outsourced Commercialization is the Revolution We Need. To effectively commercialize a product, traditional service silos stand in the way of true healthcare transformation. Do disparate service providers look at the life…
The healthcare industry is rightly focused on COVID-19 and its impact on patient care and allocation or utilization of healthcare resources. However, we cannot lose sight of our responsibility to provide appropriate therapeutic options for the…
Good news, this month’s issue of the Pricentric Newsletter is now available for download. Fill out the form below to download the Newsletter!
Why should pharmaceutical manufacturers in the rare disease space channel and communicate their inner WHY to patients? Because it’s how we can improve the adherence rate of orphan drugs from a low 60%, which the industry…
The application of clinical pathways and their enforcement through quality metric benchmark setting and appropriate use criteria is needed to guard against perverse financial incentives that encourage overutilization and underutilization. Moving forward, the more diligent payers…
The current public health pandemic is impacting healthcare stakeholders from doctors and nurses in the frontline to payers and PBMs. EVERSANA is monitoring the constant changes to access and benefit consideration tracking payer responses and key…
